Filter Results
:
(681)
Show Results For
-
All HBS Web
(1,065)
- News (156)
- Research (681)
- Events (23)
- Multimedia (1)
- Faculty Publications (431)
Show Results For
-
All HBS Web
(1,065)
- News (156)
- Research (681)
- Events (23)
- Multimedia (1)
- Faculty Publications (431)
Sort by
- 27 Sep 2011
- First Look
First Look: September 27
Even in the absence of national health coverage, the United States became the world's largest prescription drug market and emerged as the global leader in new drug research and testing. With health benefits globally from the availability of new drugs, albeit for poorer...
View Details
Keywords:
Sean Silverthorne
- 07 Apr 2015
- First Look
First Look: April 7
regularities for innovative firms. Quantifying a generalized model for the recent U.S. economy using matched Census Bureau and patent data, we observe a modest departure for external R&D from perfect scaling frameworks. Download...
View Details
Keywords:
Sean Silverthorne
- 11 Feb 2014
- First Look
First Look: February 11
further identifies how the lengths over which agglomerative forces operate influence the shapes and sizes of industrial clusters; we confirm these predictions using variations across patent technology clusters. Publisher's link:...
View Details
Keywords:
Sean Silverthorne
- 24 May 2011
- First Look
First Look: May 24
Tracleer, which Actelion sold and marketed worldwide. However, Tracleer's looming patent expiry in a few years and recent late-stage pipeline setbacks had put the company under pressure from investors. While Clozel was confident in their...
View Details
Keywords:
Sean Silverthorne
- 23 Feb 2010
- First Look
First Look: Feb. 23
engineering (SE) employment and patenting by inventors with Indian and Chinese names in cities and firms dependent upon the program relative to their peers. Most specifications find limited effects for native SE employment or patenting....
View Details
Keywords:
Martha Lagace
- 01 May 2007
- First Look
First Look: May 1, 2007
face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic drug substitution, international competitors, and complex public policy issues. This case...
View Details
Keywords:
Sean Silverthorne